Abstract:Abstract Objectives Cyclin-dependent kinase 19 (CDK19) is a component of the mediator coactivator complex, which is required for transcriptional activation. In this study, we utilized public databases and wet-bench hepatic cell line experiments to elucidate the potential roles of CDK19 in hepatocellular cancer (HCC). Materials and methods We studied the relationships between CDK19 expression and several clinical features related to HCC via the Oncomine and UALCAN databases. The prognostic value of CDK19 was tested using the Kaplan–Meier Plotter database. We presented the mutations of CDK19 and addressed the relation of CDK19 expression with immune cell infiltration by means of the cBioPortal, Catalogue of Somatic Mutations in Cancer (COSMIC) and Tumor IMmune Estimation Resource (TIMER) databases. Hub genes were obtained and further analyzed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. To test the in silico findings, we knocked down CDK19 with short hairpin RNA (shRNA) technology in two hepatic cell lines and conducted several functional characterization experiments. Results Marked CDK19 upregulation was found in HCC tissues versus normal liver tissues, and CDK19 mRNA expression had high diagnostic value in HCC patients. Subgroup analysis showed that CDK19 overexpression was associated with sex, tumor stage and TP53 mutation status. The prognostic value of CDK19 upregulation for overall survival (OS) was significant in patients with stage 2–3, stage 3–4, and grade 2 disease. One percent of the patients had CDK19 mutations, but no relationship between CDK19 mutation and prognosis was observed. CDK19 was positively correlated with the abundances of CD4 + T cells, macrophages and dendritic cells. We identified 10 genes correlated with CDK19, 8 of which presented excellent prognostic value in HCC. These hub genes were directly involved in cell division and regulation of the G2/M cell cycle transition. Protein–protein interaction (PPI) and pathway predictions indicated that CDK19 is highly likely to be involved in several cellular functions, such as proliferation, migration, and invasion. These functions were strongly interfered from two independent hepatic cell lines after CDK19 knockdown. Conclusions CDK19 could be a prognostic marker in HCC, and its therapeutic potential in HCC needs further study.

Cytokeratin19 positive hepatocellular carcinoma is associated with increased peritumoral ductular reaction.

Peritumoral ductular reaction is related to nuclear translocation of β-catenin in hepatocellular carcinoma

CK19-positive hepatocellular carcinoma is a characteristic subtype

Peritumoral Ductular Reaction Can Be a Prognostic Factor for Intrahepatic Cholangiocellular Carcinoma

Peritumoral Ductular Reaction: a Poor Postoperative Prognostic Factor for Hepatocellular Carcinoma

Circulating Tumor Cells Undergoing the Epithelial–Mesenchymal Transition: Influence on Prognosis in Cytokeratin 19-Positive Hepatocellular Carcinoma

[Diagnostic Value of Absent Ductular Reaction at Hepatocellular-Stromal Boundaries in Early Stage Hepatocellular Carcinoma].

Prognostic implications of CK19 positivity in patients with early recurrent hepatocellular carcinoma after hepatic resection undergoing transarterial chemoembolization

Cyclin-dependent Kinase 19 Upregulation Correlates with an Unfavorable Prognosis in Hepatocellular Carcinoma

Distinct prognosis of hepatocellular carcinoma with lymph node metastasis based on CK19 expression in tumor

Prognostic Value of Cytokeratin 19 in Hepatocellular Carcinoma: A Meta-Analysis.

From Proteomic Analysis to Clinical Significance: Overexpression of Cytokeratin 19 Correlates with Hepatocellular Carcinoma Metastasis

Differences in cytochrome P4502C19 (CYP2C19) expression in adjacent normal and tumor tissues in chinese cancer patients

[Study on the Relationship Between Serum Cytokeratin 19 Level in Hepatocellular Carcinoma Patients and the Clinico-Pathologic Characteristics].

MR Features Based on LI-RADS Ver. 2018 Correlated with Cytokeratin 19 Expression in Combined Hepatocellular Carcinoma-Cholangiocarcinoma

Hepatocellular carcinoma expressing cholangiocyte phenotype is a novel subtype with highly aggressive behavior

Perinodular Ductular Reaction/epithelial Cell Adhesion Molecule Loss in Small Hepatic Nodules

Association of CK19 Expression with the Efficacy of Adjuvant Transarterial Chemoembolization after Hepatic Resection in Hepatocellular Carcinoma Patients at High Risk of Recurrence.

Cytokeratin 10 and Cytokeratin 19: Predictive Markers for Poor Prognosis in Hepatocellular Carcinoma Patients after Curative Resection

Assessment of cytokeratin 19 expression in hepatocellular carcinoma by MRI based on LI-RADS